Norway-based clinical-stage biopharmaceutical company BerGenBio ASA (OSE: BGBIO) on Monday announced preliminary safety data from the Phase 1b portion of its BGBC016 study in first-line Non-Small Cell Lung Cancer (NSCLC) patients.
The study assessed three escalating doses of bemcentinib, a selective AXL kinase inhibitor, in combination with standard chemo-immunotherapy, doublet chemotherapy and pembrolizumab (Keytruda). The primary endpoint focused on safety, with results showing the combination was well tolerated across all doses with no new safety signals. No dose-related electrocardiographic changes (QTc) were observed.
Pharmacokinetic analyses confirmed adequate plasma exposure of bemcentinib, consistent with previous responder data from the BGBC008 study in second-line NSCLC patients. These findings support further development of bemcentinib in combination with chemo-immunotherapy for advanced NSCLC.
TNF Pharmaceuticals showcases isomyosamine's clinical promise at BGS Spring Meeting 2025
Bruker acquires majority stake in RECIPE to expand clinical mass spectrometry diagnostics
Hoth Therapeutics reports positive initial data from Phase 2a pruritus trial
Galmed reveals novel pharmacodynamic blood markers for Aramchol SCD1 inhibitor
Evommune initiates EVO756 Phase 2b trial in adults with chronic spontaneous urticaria
Telix Pharmaceuticals' TLX101 glioma therapy candidate shows promising efficacy
FluoGuide begins phase II trial of FG001 for head and neck cancer
Sanofi advances respiratory pipeline with positive amlitelimab data and expanded clinical programmes
Sumitomo Pharma America signs research and development agreement with NCI
IDEAYA Biosciences advances Phase 3 design for darovasertib in primary uveal melanoma
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Genflow Biosciences enters into AI-driven research agreement with Heureka Labs